小细胞肺癌的维持或巩固治疗:最新的系统综述和荟萃分析。

IF 3 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2022-10-01 DOI:10.1053/j.seminoncol.2022.09.001

Lorenzo Belluomini , Sara Pilotto , Alice Avancini , Jessica Insolda , Marco Sposito , Jessica Menis , Chiara Ciccarese , Roberto Iacovelli , Miriam Grazia Ferrara , Michele Milella , Emilio Bria , Antonio Rossi

{"title":"小细胞肺癌的维持或巩固治疗:最新的系统综述和荟萃分析。","authors":"Lorenzo Belluomini , Sara Pilotto , Alice Avancini , Jessica Insolda , Marco Sposito , Jessica Menis , Chiara Ciccarese , Roberto Iacovelli , Miriam Grazia Ferrara , Michele Milella , Emilio Bria , Antonio Rossi","doi":"10.1053/j.seminoncol.2022.09.001","DOIUrl":null,"url":null,"abstract":"<div>We performed an updated meta-analysis to explore the role of maintenance therapy in SCLC. Clinical trials with randomization to maintenance/consolidation (V) placebo or observation or best supportive care in SCLC, both extended and limited disease were searched from January 2009 to March 2022. The hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence interval (CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies. A total of 9 studies were identified. Neither PFS nor OS were improved with maintenance/consolidation (PFS: random-effect; HR 0.93; 95% CI 0.71–1.21; P=0.10; OS: fixed-effect; HR 0.98; 95% CI 0.89–1.08; P=0.14). Among the different strategies, immunotherapy maintenance showed a significantly decreased risk of progression (V)standard of care (random-effect; HR 0.80; 95% CI 0.66–0.97; P=0.03). The current updated meta-analysis did not demonstrate a benefit of maintenance/consolidation therapy in SCLC, with only a PFS benefit for immunotherapy approach.</div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"49 5","pages":"Pages 389-393"},"PeriodicalIF":3.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.\",\"authors\":\"Lorenzo Belluomini , Sara Pilotto , Alice Avancini , Jessica Insolda , Marco Sposito , Jessica Menis , Chiara Ciccarese , Roberto Iacovelli , Miriam Grazia Ferrara , Michele Milella , Emilio Bria , Antonio Rossi\",\"doi\":\"10.1053/j.seminoncol.2022.09.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>We performed an updated meta-analysis to explore the role of maintenance therapy in SCLC. Clinical trials with randomization to maintenance/consolidation (V) placebo or observation or best supportive care in SCLC, both extended and limited disease were searched from January 2009 to March 2022. The hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence interval (CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies. A total of 9 studies were identified. Neither PFS nor OS were improved with maintenance/consolidation (PFS: random-effect; HR 0.93; 95% CI 0.71–1.21; P=0.10; OS: fixed-effect; HR 0.98; 95% CI 0.89–1.08; P=0.14). Among the different strategies, immunotherapy maintenance showed a significantly decreased risk of progression (V)standard of care (random-effect; HR 0.80; 95% CI 0.66–0.97; P=0.03). The current updated meta-analysis did not demonstrate a benefit of maintenance/consolidation therapy in SCLC, with only a PFS benefit for immunotherapy approach.</div>\",\"PeriodicalId\":21750,\"journal\":{\"name\":\"Seminars in oncology\",\"volume\":\"49 5\",\"pages\":\"Pages 389-393\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0093775422000616\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775422000616","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

我们进行了一项最新的荟萃分析，以探讨维持治疗在SCLC中的作用。从2009年1月到2022年3月，研究人员检索了SCLC中随机分配到维持/巩固(V)安慰剂或观察或最佳支持治疗的临床试验，包括扩展和有限疾病。从每项研究中提取无进展生存期(PFS)和总生存期(OS)的风险比(HR)和相对95%置信区间(CI)。根据纳入研究的异质性，采用随机或固定效应模型计算HR。总共确定了9项研究。PFS和OS均未因维持/巩固而改善(PFS:随机效应;人力资源0.93;95% ci 0.71-1.21;P = 0.10;操作系统:固定效果;人力资源0.98;95% ci 0.89-1.08;P = 0.14)。在不同的策略中，免疫治疗维持显示出进展风险显著降低(V)标准护理(随机效应;人力资源0.80;95% ci 0.66-0.97;P = 0.03)。当前更新的荟萃分析没有证明维持/巩固治疗对SCLC的益处，只有免疫治疗方法的PFS益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.

We performed an updated meta-analysis to explore the role of maintenance therapy in SCLC. Clinical trials with randomization to maintenance/consolidation (V) placebo or observation or best supportive care in SCLC, both extended and limited disease were searched from January 2009 to March 2022. The hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence interval (CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies. A total of 9 studies were identified. Neither PFS nor OS were improved with maintenance/consolidation (PFS: random-effect; HR 0.93; 95% CI 0.71–1.21; P=0.10; OS: fixed-effect; HR 0.98; 95% CI 0.89–1.08; P=0.14). Among the different strategies, immunotherapy maintenance showed a significantly decreased risk of progression (V)standard of care (random-effect; HR 0.80; 95% CI 0.66–0.97; P=0.03). The current updated meta-analysis did not demonstrate a benefit of maintenance/consolidation therapy in SCLC, with only a PFS benefit for immunotherapy approach.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.